In the context of nephrology, the AHA position provides an important recommendation: clinicians should assess the urinary albumin-to-creatinine ratio, in addition to the estimated GFR, in patients with CKD, T2DM, hypertension, and metabolic syndrome, to fully characterize the risk of CKD and CVD, particularly heart failure. This evidence concerns the gene ALB and chronic kidney disease.